Primary nonbronchogenic small-cell carcinoma has been described in a number of extrapulmonary sites, including the salivary glands, prostate, breast, esophagus, bladder, and cervix [1]. Primary small-cell gastric neuroendocrine carcinomas are extremely rare, representing less than 0.1% of all primary gastric cancers [2].

A 59-year-old woman presented with a 2-month history of intermittent chest pain, nausea, dizziness, diaphoresis, and nonbloody emesis. She had lost 20 lb in weight, but she said that she did not have early satiety or abdominal pain. Her hemoglobin level was 6.1 g/dL, with an iron saturation of 7%. Computed tomography did not show any lung or pancreatic masses. Upper endoscopy revealed a 5-cm ulcer with a necrotic base and friable, irregular borders on the lesser curvature of the stomach.

Histologically, the malignant tumor showed solid, organoid, trabecular, and pseudoglandular patterns. The tumor cells showed a high nuclear grade, with minimal cytoplasm, indistinct nucleoli, and nuclear molding, and there was clear evidence of increased mitotic activity and necrosis (Figure 3). Immunohistochemical staining, with adequate controls, showed the tumor cells to be strongly positive for pancytokeratin, synaptophysin, and CD56 (Figures 4 – 6), but negative for chromogranin A. Staining for TTF-1, a tissue-specific transcription factor that is specific to thyroid, lung, and brain tissues [3] was negative. This combination of histopathological and immunohistochemical findings was compatible with a high-grade primary small-cell neuroendocrine carcinoma of the stomach. The patient declined further evaluation and management.

Gastric neuroendocrine carcinoma is one of the most aggressive cancers, and has an extremely poor prognosis. To date, only 38 cases have been reported (34 of them in Japan) since the first description of the tumor in 1976 [2, 4]. Most cases have been described in male patients. Our patient is an African American woman from the United States, which makes this case even more interesting and unique. Because of the rarity of these cancers, the classification and biological characteristics of primary gastric neuroendocrine carcinomas remain controversial, and neuroendocrine differentiation is recognized only after appropriate immunohistochemical staining. The literature describes synaptophysin, chromogranin A, CD56, and other immunohistochemical markers as reliable for detecting neuroendocrine differentiation; and the CD56 marker is also being helpful for differentiating between small-cell and large-cell carcinomas [5].

**Acknowledgment**

The authors wish to thank Dr. Enrique Gomez from the Department of Pathology at the University of Texas-Houston for his assistance in the preparation and inter-
pretation of the histopathology specimens.

A. Shpaner, T. E. Yusuf
Division of Gastroenterology,
The University of Texas Health Science Center at Houston, Houston, Texas, USA

References

Bibliography
Endoscopy 2007; 39: E310 – E311
© Georg Thieme Verlag KG Stuttgart - New York - ISSN 0013-726X

Corresponding author
T. E. Yusuf, MD
Division of Gastroenterology
The University of Texas Health Science Center at Houston
6431 Fannin Street, Suite 4.234
Houston
Texas 77030
USA
Fax: +1-713-500-6699
tony.yusuf@uth.tmc.edu

Figure 6 Microscopic view of the gastric neuroendocrine carcinoma biopsy tissue, showing positive staining for the CD56 marker (original magnification × 20).